Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Prin. Fin. and Acctg. Officer | April 12, 2023 | April 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date April 12, 2023 · Filed April 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,853 |
Reported balance
After 2023-04-12 transaction · row 1
1 source rowRow 1 · 2023-04-12 · Exercise / conversion · Acquired 50,000 · Balance 61,853 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2023-04-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-12 · Exercise / conversion · Disposed 50,000 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs). F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2023 Filed Apr 14, 2023 23:17 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024386 · doc4.xml · derivative · entry 2 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs). F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. F2 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:17 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024386 · doc4.xml · nonDerivative · entry 1 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:11 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012271 · doc4.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023. F1 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 49 | $5.09 | $249.41 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 5 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,853 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionPerformance Stock Units · Derivative | 1,140 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · derivative · entry 8 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). F4 · derivative.exercise_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F4 · derivative.expiration_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionPerformance Stock Units · Derivative | 2,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · derivative · entry 7 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). F4 · derivative.exercise_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F4 · derivative.expiration_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionPerformance Stock Units · Derivative | 2,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · derivative · entry 6 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). F4 · derivative.exercise_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F4 · derivative.expiration_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 1,648 | $5.08 | $8,371.18 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 4 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,902 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 3 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 2 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 23:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 1 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 7 | $5.31 | $37.17 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 6 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,610 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 2,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 10 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). F7 · derivative.exercise_date: The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F7 · derivative.expiration_date: The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 519 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 9 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). F6 · derivative.exercise_date: Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F6 · derivative.expiration_date: Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 1,066 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 8 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). F5 · derivative.exercise_date: The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F5 · derivative.expiration_date: The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 7 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). F4 · derivative.exercise_date: The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". F4 · derivative.expiration_date: The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 1,302 | $5.34 | $6,950.47 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 5 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,617 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 4 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 519 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 3 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 2 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 1 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 262 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 9 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519 Underlying: Common Stock · 262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). F7 · derivative.exercise_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024. F7 · derivative.expiration_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 534 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 8 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,066 Underlying: Common Stock · 534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). F6 · derivative.exercise_date: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. F6 · derivative.expiration_date: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 7 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). F5 · derivative.exercise_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F5 · derivative.expiration_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 2,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 6 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). F4 · derivative.exercise_date: The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022. F4 · derivative.expiration_date: The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 910 | $4.78 | $4,345.25 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 5 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,554 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 4 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 534 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 3 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 2 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 1 Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 21:15 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 120,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021792 · doc4.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · derivative.exercise_date: The performance stock units ("PSUs") vest on April 5, 2025 based the total shareholder return ("TSR") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: The performance stock units ("PSUs") vest on April 5, 2025 based the total shareholder return ("TSR") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: The performance stock units ("PSUs") vest on April 5, 2025 based the total shareholder return ("TSR") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 23, 2022 Filed Mar 28, 2022 11:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 120,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021209 · doc4.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. F1 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 11:30 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 115,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067391 · doc4.xml · derivative · entry 3 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021. F4 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5 · derivative.exercise_date: The RSUs vest in two equal installments on November 24, 2021 and November 24, 2022. F5 · derivative.expiration_date: The RSUs vest in two equal installments on November 24, 2021 and November 24, 2022. F1 · derivative.underlying_shares: On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021. F4 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 11:30 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 29,790 | $0.54 | $15,946.59 |
DisclosureSEC source: 0001209191-21-067391 · doc4.xml · nonDerivative · entry 2 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,368 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $0.4819 to $0.5503 for an average weighted sale price of $0.5353. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 11:30 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 115,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-067391 · doc4.xml · nonDerivative · entry 1 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-21-058498 · doc4.xml · derivative · entry 5 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-03-15 F3 · kind: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F3 · shares: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F7 · derivative.exercise_date: Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant. F7 · derivative.expiration_date: Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-21-058498 · doc4.xml · derivative · entry 4 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2027-03-14 F3 · kind: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F3 · shares: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F6 · derivative.exercise_date: Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant. F6 · derivative.expiration_date: Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0001209191-21-058498 · doc4.xml · derivative · entry 3 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-12-17 F3 · kind: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F3 · shares: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F5 · derivative.exercise_date: Underlying shares were subject to vesting as follows: equal monthly installments over 12 months. F5 · derivative.expiration_date: Underlying shares were subject to vesting as follows: equal monthly installments over 12 months. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | OtherNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-21-058498 · doc4.xml · derivative · entry 2 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-07-09 F3 · kind: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F3 · shares: Stock options exchanged for RSUs pursuant to the Option Exchange Program. F4 · derivative.exercise_date: Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant. F4 · derivative.expiration_date: Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 38,954 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058498 · doc4.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · CAO and VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,954 Underlying: Common Stock · 38,954 shares Expires not disclosed F1 · shares: Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the "Option Exchange Program"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:42 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 80,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007114 · ownership.xml · derivative · entry 2 Donegan Michael C · CIK 0001627810 · CAO and VP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:42 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 160,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007114 · ownership.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · CAO and VP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires not disclosed F1 · shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| May 11, 2021 Filed May 13, 2021 00:44 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 4,842 | $1.04 | $5,035.68 |
DisclosureSEC source: 0001387131-21-005571 · ownership.xml · nonDerivative · entry 2 Donegan Michael C · CIK 0001627810 · CAO and VP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,158 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:44 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-005571 · ownership.xml · derivative · entry 3 Donegan Michael C · CIK 0001627810 · CAO and VP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2021, the reporting person received 19,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. F4 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5 · derivative.exercise_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F5 · derivative.expiration_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F4 · balance_after: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:44 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-005571 · ownership.xml · nonDerivative · entry 1 Donegan Michael C · CIK 0001627810 · CAO and VP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 10, 2021, the reporting person received 19,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 22:09 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 230,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-010309 · ownership.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in two equal installments on November 24, 2021 and November 24, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in two equal installments on November 24, 2021 and November 24, 2022. Read SEC document |
| March 30, 2020 Filed Apr 2, 2020 00:30 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 57,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-003589 · donegan-form4_033020.xml · derivative · entry 2 Donegan Michael C · CIK 0001627810 · Vice President Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. Read SEC document |
| March 30, 2020 Filed Apr 2, 2020 00:30 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 57,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-003589 · donegan-form4_033020.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · Vice President Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires not disclosed F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| August 28, 2019 Filed Aug 31, 2019 01:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001387131-19-006607 · ownership.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · Vice President Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-08-28 F1 · derivative.exercise_date: Underlying shares vest as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 21:45 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001387131-18-001125 · donegan-form4_031518.xml · derivative · entry 1 Donegan Michael C · CIK 0001627810 · Vice President Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: Underlying shares vest as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.